Drugs / CYWC628
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07096934 | Sep 2025 → Mar 2026 overdue | ulcer of lower limbs | FibroBiologics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-03-12 | FibroBiologics | Results FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology fibrobiologics.com ↗
In preclinical burn models, treatment with proprietary fibroblast spheroids (CYWC628) was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair and wound healing in skin. |
| 2025-11-20 | FibroBiologics | Regulatory FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers fibrobiologics.com ↗ |
| 2025-05-16 | FibroBiologics | Results FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting fibrobiologics.com ↗
The poster highlighted FibroBiologics’ human dermal fibroblast (HDF) spheroids potential to reduce psoriasis severity in preclinical models, and offer a scalable, cell-based therapy with durable effects. |
All press releases naming this drug 12 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYWC628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096934 ↗ |
| Known as | Human Dermal Fibroblast Spheroids | “CYWC628 (Human Dermal Fibroblast Spheroids)” NCT07096934 ↗ |